{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:25:04Z","timestamp":1791645904622,"version":"4.3.4"},"reference-count":100,"publisher":"European Respiratory Society (ERS)","issue":"122","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2011,9,8]]},"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a severe and debilitating disease characterised by vascular proliferation and remodelling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance, increased afterload on the right ventricle and, ultimately, right heart failure. Although there is no \u201ccure\u201d for PAH, the availability of targeted therapies over the past decade has led to major advances in the management of PAH, reflected in improvements in survival in the modern treatment era. However, despite this, disease progression is inevitable in the majority of patients with PAH and overall the long-term prognosis, although improved, remains poor. There is a clear and urgent need for new therapeutic options, either through the development of improved drugs that act on targets established by existing PAH-specific therapies, or of agents targeting novel pathogenic pathways not addressed by currently available therapies. A number of such new agents that have shown promise in experimental models and preliminary human studies are discussed in this article.<\/jats:p>","DOI":"10.1183\/09059180.00006411","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T13:24:13Z","timestamp":1322832253000},"page":"262-269","source":"Crossref","is-referenced-by-count":51,"title":["Looking to the future: a new decade of pulmonary arterial hypertension therapy"],"prefix":"10.1183","volume":"20","author":[{"given":"V.V.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2011,11,30]]},"reference":[{"key":"2025042404454473000_20.122.262.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"2025042404454473000_20.122.262.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2025042404454473000_20.122.262.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"2025042404454473000_20.122.262.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2208008"},{"key":"2025042404454473000_20.122.262.5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1053-2498(00)00606-9","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study","volume":"20","author":"Channick","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"2025042404454473000_20.122.262.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.247"},{"key":"2025042404454473000_20.122.262.7","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.040618"},{"key":"2025042404454473000_20.122.262.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2025042404454473000_20.122.262.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00054804"},{"key":"2025042404454473000_20.122.262.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"2025042404454473000_20.122.262.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1028"},{"key":"2025042404454473000_20.122.262.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"2025042404454473000_20.122.262.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01256.x"},{"key":"2025042404454473000_20.122.262.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.1.5"},{"key":"2025042404454473000_20.122.262.15","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.23.1.4030"},{"key":"2025042404454473000_20.122.262.16","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","article-title":"Polar secretion of endothelin-1 by cultured endothelial cells","volume":"267","author":"Wagner","year":"1992","journal-title":"J Biol Chem"},{"key":"2025042404454473000_20.122.262.17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142976"},{"key":"2025042404454473000_20.122.262.18","first-page":"1066","article-title":"Macitentan: a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis","volume":"11","author":"Raja","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"2025042404454473000_20.122.262.19","unstructured":"ClinicalTrials.gov. Study of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. NCT00660179. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00660179 Date last updated: May 20, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.007"},{"key":"2025042404454473000_20.122.262.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-7-485"},{"key":"2025042404454473000_20.122.262.22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-6-199409150-00003"},{"key":"2025042404454473000_20.122.262.23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029100.82385.58"},{"key":"2025042404454473000_20.122.262.24","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"2025042404454473000_20.122.262.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00044406"},{"key":"2025042404454473000_20.122.262.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"2025042404454473000_20.122.262.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.01.008"},{"key":"2025042404454473000_20.122.262.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00130408"},{"key":"2025042404454473000_20.122.262.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.070"},{"key":"2025042404454473000_20.122.262.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.062"},{"key":"2025042404454473000_20.122.262.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"2025042404454473000_20.122.262.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"2025042404454473000_20.122.262.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"2025042404454473000_20.122.262.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.07.015"},{"key":"2025042404454473000_20.122.262.35","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.124248"},{"key":"2025042404454473000_20.122.262.36","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.138305"},{"key":"2025042404454473000_20.122.262.37","first-page":"A2515","article-title":"Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH)","volume":"181","author":"Simonneau","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042404454473000_20.122.262.38","unstructured":"ClinicalTrials.gov. ACT-293987 in pulmonary arterial hypertension. NCT01106014. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01106014 Date last updated: July 27, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.39","first-page":"A1040","article-title":"Results of the FREEDOM-C Study: a pivotal study of oral treprostinil used adjunctively with an ERA and\/or PDE5-inhibitor for the treatment of PAH","volume":"179","author":"Tapson","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042404454473000_20.122.262.40","unstructured":"United Therapeutics. FREEDOM-M Trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint. http:\/\/ir.unither.com\/releasedetail.cfm?ReleaseID=582786 Date last updated: June 6, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.41","unstructured":"ClinicalTrials.gov. An open-label extension trial of UT-15C SR in subjects with pulmonary arterial hypertension (FREEDOM-EXT). NCT 01027949. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01027949 Date last updated October 8, 2010. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.42","unstructured":"ClinicalTrials.gov. A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension (FREEDOM-C2). NCT00887978. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00887978 Date last updated: May 5, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.43","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328332bcdb"},{"key":"2025042404454473000_20.122.262.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507273330403"},{"key":"2025042404454473000_20.122.262.45","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.2.7842196"},{"key":"2025042404454473000_20.122.262.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2025042404454473000_20.122.262.47","doi-asserted-by":"crossref","unstructured":"Rubin LJ Badesch DB Fleming TR . Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 2011; [Epub ahead of print DOI: 10.1378\/chest.10-0969].","DOI":"10.1378\/chest.10-0969"},{"key":"2025042404454473000_20.122.262.48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"2025042404454473000_20.122.262.49","doi-asserted-by":"publisher","DOI":"10.2217\/fca.10.5"},{"key":"2025042404454473000_20.122.262.50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-1121OC"},{"key":"2025042404454473000_20.122.262.51","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00182909"},{"key":"2025042404454473000_20.122.262.52","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200900014"},{"key":"2025042404454473000_20.122.262.53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24838"},{"key":"2025042404454473000_20.122.262.54","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00114407"},{"key":"2025042404454473000_20.122.262.55","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00039808"},{"key":"2025042404454473000_20.122.262.56","unstructured":"ClinicalTrials.gov. A study to evaluate efficacy and safety of oral BAY63-2521 in patients with pulmonary arterial hypertension (PAH) (PATENT-1). NCT00810693. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00810693 Date last updated: August 4, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.57","unstructured":"ClinicalTrials.gov. A study to evaluate efficacy and safety of oral BAY63-2521 in patients with CTEPH (CHEST-1). NCT00855465. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00855465 Date last updated: July 27, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.58","doi-asserted-by":"crossref","unstructured":"Paulin R Courboulin A Barrier M . From oncoproteins\/tumor suppressors to microRNAs: the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl) 2011; [Epub ahead of print DOI: 10.1007\/s00109-011-0788-5].","DOI":"10.1007\/s00109-011-0788-5"},{"key":"2025042404454473000_20.122.262.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.07.003"},{"key":"2025042404454473000_20.122.262.60","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.779751"},{"key":"2025042404454473000_20.122.262.61","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9227-1"},{"key":"2025042404454473000_20.122.262.62","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-500-2_28"},{"key":"2025042404454473000_20.122.262.63","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"2025042404454473000_20.122.262.64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26593"},{"key":"2025042404454473000_20.122.262.65","doi-asserted-by":"crossref","unstructured":"Nakamura K Akagi S Ogawa A . Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2011; [Epub ahead of print DOI: 10.1016\/j.ijcard.2011.02.024].","DOI":"10.1016\/j.ijcard.2011.02.024"},{"key":"2025042404454473000_20.122.262.66","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.51.272"},{"key":"2025042404454473000_20.122.262.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc051946"},{"key":"2025042404454473000_20.122.262.68","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2025042404454473000_20.122.262.69","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.064097"},{"key":"2025042404454473000_20.122.262.70","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-009-0752-3"},{"key":"2025042404454473000_20.122.262.71","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0300-2896(08)75779-X","article-title":"Experience with imatinib to treat pulmonary arterial hypertension","volume":"44","author":"Garc\u00eda Hern\u00e1ndez","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"2025042404454473000_20.122.262.72","unstructured":"ClinicalTrials.gov. Imatinib in pulmonary arterial hypertension (IMPRES). NCT00902174. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00902174 Date last updated: December 1, 2010. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.73","unstructured":"ClinicalTrials.gov. Extension to QTI571A2301 to evaluate the long-term safety, tolerability and efficacy of imatinib in severe pulmonary arterial hypertension (IMPRES Extn). NCT01117987. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01117987 Date last updated: October 22, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"2025042404454473000_20.122.262.75","first-page":"A6304","article-title":"Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension","volume":"181","author":"Duggan","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042404454473000_20.122.262.76","unstructured":"ClinicalTrials.gov. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). NCT01179737. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179737 Date last updated: August 10, 2010. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"2025042404454473000_20.122.262.78","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.241"},{"key":"2025042404454473000_20.122.262.79","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80156-9"},{"key":"2025042404454473000_20.122.262.80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200112805"},{"key":"2025042404454473000_20.122.262.81","doi-asserted-by":"crossref","first-page":"H1173","DOI":"10.1152\/ajpheart.1997.272.3.H1173","article-title":"Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats","volume":"41","author":"Eddahibi","year":"1997","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025042404454473000_20.122.262.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.09.023"},{"key":"2025042404454473000_20.122.262.83","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.524926"},{"key":"2025042404454473000_20.122.262.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2006.01.001"},{"key":"2025042404454473000_20.122.262.85","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2823"},{"key":"2025042404454473000_20.122.262.86","doi-asserted-by":"publisher","DOI":"10.1161\/hh2401.100426"},{"key":"2025042404454473000_20.122.262.87","doi-asserted-by":"publisher","DOI":"10.1038\/nm764"},{"key":"2025042404454473000_20.122.262.88","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00126010"},{"key":"2025042404454473000_20.122.262.89","unstructured":"Ergonex. Ergonex Pharma initiates Phase II clinical trial of terguride in pulmonary arterial hypertension. www.ergonex.com\/attachments\/news\/26\/Media_Release_final_V2.pdf Date last updated: January 29, 2008. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"2025042404454473000_20.122.262.91","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-500-2_27"},{"key":"2025042404454473000_20.122.262.92","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.217"},{"key":"2025042404454473000_20.122.262.93","unstructured":"ClinicalTrials.gov. Sorafenib study: dosing in patients with pulmonary arterial hypertension (PAH). NCT00452218. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00452218 Date last updated: August 2, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.94","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000164391.72968.84"},{"key":"2025042404454473000_20.122.262.95","doi-asserted-by":"publisher","DOI":"10.3109\/01902148.2010.512972"},{"key":"2025042404454473000_20.122.262.96","unstructured":"ClinicalTrials.gov. 6R-BH4 pulmonary arterial hypertension study. NCT00435331. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00435331 Date last updated: April 17, 2011. Date last accessed: August 9, 2011."},{"key":"2025042404454473000_20.122.262.97","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000145360.16770.9f"},{"key":"2025042404454473000_20.122.262.98","doi-asserted-by":"publisher","DOI":"10.1161\/hc0202.101974"},{"key":"2025042404454473000_20.122.262.99","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-131664"},{"key":"2025042404454473000_20.122.262.100","unstructured":"ClinicalTrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension. NCT01083524. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01083524 Date last updated: March 9, 2010. Date last accessed: August 9, 2011."}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09059180.00006411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:46:03Z","timestamp":1745495163000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09059180.00006411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,30]]},"references-count":100,"journal-issue":{"issue":"122","published-online":{"date-parts":[[2011,11,30]]},"published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1183\/09059180.00006411"],"URL":"https:\/\/doi.org\/10.1183\/09059180.00006411","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,30]]}}}